logo
Plus   Neg
Share
Email

FDA Approves First Quadrivalent Flu Vaccine

sneeze-030112.jpg

FluMist Quadrivalent, a vaccine developed by AstraZeneca plc's (AZN) MedImmune unit, has been approved by the FDA for the prevention of seasonal influenza in people aged 2 years through 49 years.

FluMist Quadrivalent is the first influenza vaccine to contain four strains of the influenza virus - two influenza A strains and two influenza B strains. All other currently available licensed seasonal influenza vaccines, are trivalent, containing only three influenza virus strains namely, two strains of influenza A and one of influenza B.

Some of the approved trivalent flu vaccines are CSL Biotherapies' Afluria; Novartis' Agriflu; GlaxoSmithKline's Fluarix; ID Biomedical Corp.'s FluLaval; MedImmune's FluMist, and Sanofi Pasteur Inc.'s Fluzone and Fluzone High-Dose.

According to federal health officials, FluMist Quadrivalent increases the likelihood of adequate protection against circulating influenza B strains.

The newly approved FluMist Quadrivalent is administered as a spray into the nose, similar to the trivalent FluMist vaccine.

Influenza, commonly referred to as flu, is a contagious viral infection, associated with aches, pains, tiredness, sore throat and a runny nose. The symptoms may last from three to five days and can make a person quite ill for a few weeks.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Each year, more than eight million children die from preventable diseases in countries with the worst health care systems . Kofi Annan, former head of the UN, said that, "Almost all these deaths will happen in developing countries. A large number of them could be prevented." You do not want to find... As Canada prepares to legalize marijuana nationwide later this year, a national survey by Statistics Canada has thrown up some interesting facts - including that legal marijuana is not a temptation for most Canadians. Regardless of cannabis use, 79 percent of Canadians surveyed said they would not be more likely to try or increase their cannabis consumption just because it is legalized. The Procter & Gamble Company (PG) reported third-quarter net earnings per share of $0.95, an increase of two percent versus the prior year. Net earnings from continuing operations declined 1% year-over-year to $2.54 billion. Core earnings per share increased four percent to $1.00. On average, 20 analysts...
Follow RTT